Ranbaxy, Inc.

Let me verify the litigation context around the Jazz Pharmaceuticals cases.

Ranbaxy Inc. was the U.S. operating subsidiary of Ranbaxy Laboratories Limited, an Indian generic-drug manufacturer founded in 1961 (incorporated 1962) and headquartered in Gurgaon, Haryana, India. Ranbaxy went public on Indian exchanges in 1973. Japan's Daiichi Sankyo acquired a 63.4% controlling stake in 2008 for roughly $4.6 billion. In April 2014 Sun Pharmaceutical Industries agreed to acquire Ranbaxy in an all-stock deal (~$4 billion enterprise value); the merger closed in March 2015, Ranbaxy was delisted, and the Ranbaxy corporate brand was retired, with its U.S. operations folded into Sun Pharma. Ranbaxy Inc. therefore no longer exists as a distinct entity. Historically the group reported about $1.18 billion in revenue (2004) with several thousand employees; at the time of the Sun deal, the combined company was described as the world's fifth-largest specialty generics maker, with projected revenue above $4.2 billion.

Operations. Ranbaxy manufactured and marketed generic prescription pharmaceuticals and active pharmaceutical ingredients across the U.S., India, Europe, Brazil, Russia and Africa, and held a portfolio of OTC consumer-health brands (including Volini and Revital). It also pursued first-to-file generic opportunities (e.g., generic Diovan, Nexium and Valcyte) and some novel drug-delivery research. The operations were substantially disrupted by FDA import alerts and a $500 million U.S. Department of Justice settlement in 2013.

Litigation posture. Ranbaxy was an operating company, not a patent assertion entity. In the tracked data it appears as defendant in five Hatch-Waxman ANDA suits and as plaintiff in two PTAB inter partes reviews — a classic two-way generics posture: sued for infringement, and counter-challenging the asserted patents. Cases clustered in the District of New Jersey, not plaintiff-friendly venues such as the Eastern District of Texas.

Notable cases. All tracked matters involve Jazz Pharmaceuticals and the narcolepsy drug Xyrem (sodium oxybate). Jazz sued Ranbaxy in D.N.J. in July 2014 over Ranbaxy's ANDA No. 203351 and 14 Orange Book patents; Ranbaxy filed IPRs against Jazz's patents (including U.S. 8,772,306, the valproate-interaction patent) in late 2015/early 2016. The parties settled on May 9, 2016, granting Ranbaxy a license to launch a generic Xyrem on or after December 31, 2025, with the IPRs terminated.

Sources: Sun Pharma/Daiichi Sankyo press releases; NYT DealBook (2014); NDTV Profit/DNA India; Reference for Business; National Law Review; Jazz Pharmaceuticals SEC filings.